# Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab

> **NCT04536922** · PHASE2 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Metastatic HPV-16 Positive Squamous Cell Anal Cancer

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Aldesleukin
- **DRUG:** Pembrolizumab (KEYTRUDA(R))
- **BIOLOGICAL:** Individual Patient TCR-Transduced PBL

## Key facts

- **NCT ID:** NCT04536922
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-01-27
- **Primary completion:** 2021-01-27
- **Final completion:** 2021-01-27
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Subject no longer able to participate in this single pt study.
- **Last updated:** 2021-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04536922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04536922, "Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04536922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*